News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
2,862 Results
Type
Article (328)
Company Profile (1)
Press Release (2533)
Section
Business (1004)
Career Advice (10)
Deals (139)
Drug Delivery (6)
Drug Development (678)
FDA (96)
Job Trends (150)
News (1891)
Policy (186)
Tag
Academia (4)
Alliances (367)
Alzheimer's disease (4)
Antibody-drug conjugate (ADC) (30)
Approvals (97)
Artificial intelligence (3)
Bankruptcy (1)
Best Places to Work (125)
Biosimilars (2)
Bladder cancer (2)
Breast cancer (33)
Cancer (78)
Cardiovascular disease (2)
Career advice (8)
Cell therapy (1)
Clinical research (594)
Collaboration (7)
Complete response letters (2)
COVID-19 (5)
C-suite (2)
Data (15)
Diabetes (1)
Diagnostics (15)
Drug discovery (2)
Drug pricing (4)
Drug shortages (1)
Duchenne muscular dystrophy (1)
Earnings (332)
Editorial (2)
Events (311)
Executive appointments (3)
FDA (105)
Funding (1)
Gene therapy (3)
GLP-1 (7)
Government (12)
Healthcare (30)
Immunology and inflammation (1)
Infectious disease (5)
Inflation Reduction Act (1)
Intellectual property (1)
Interviews (1)
IPO (52)
IRA (1)
Job creations (31)
Job search strategy (8)
Layoffs (4)
Legal (41)
Liver cancer (1)
Lung cancer (29)
Lymphoma (1)
Manufacturing (6)
Medical device (8)
Medtech (8)
Mergers & acquisitions (86)
Metabolic disorders (2)
Neurodegenerative disease (1)
Neuroscience (4)
NextGen: Class of 2025 (15)
Non-profit (12)
Now hiring (9)
Obesity (1)
Opinion (8)
Ovarian cancer (4)
Pain (1)
Patents (4)
People (272)
Pharmaceutical (1)
Phase I (153)
Phase II (210)
Phase III (297)
Pipeline (7)
Policy (1)
Postmarket research (34)
Preclinical (23)
Prostate cancer (1)
Psychedelics (1)
Radiopharmaceuticals (1)
Rare diseases (3)
Real estate (11)
Regulatory (160)
Research institute (9)
Resumes & cover letters (1)
Schizophrenia (1)
Series A (1)
Special edition (1)
Sponsored (1)
Startups (14)
Stomach cancer (3)
The Weekly (3)
Vaccines (2)
Weight loss (1)
Date
Today (1)
Last 7 days (3)
Last 30 days (15)
Last 365 days (164)
2025 (61)
2024 (166)
2023 (139)
2022 (330)
2021 (229)
2020 (198)
2019 (198)
2018 (129)
2017 (167)
2016 (102)
2015 (123)
2014 (101)
2013 (68)
2012 (77)
2011 (125)
2010 (106)
Location
Africa (4)
Asia (525)
Australia (42)
California (14)
Canada (4)
China (1)
Colorado (1)
Delaware (13)
Europe (444)
Florida (1)
Illinois (1)
Japan (16)
Maryland (1)
Massachusetts (2)
New Jersey (30)
New York (4)
Northern California (10)
Pennsylvania (1)
South America (5)
Southern California (2)
Texas (1)
United States (71)
Virginia (1)
Washington State (1)
Wisconsin (1)
2,862 Results for "daiichi sankyo".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Cancer
AstraZeneca/Daiichi Sankyo, BioNTech, Merus to Present Promising Cancer Therapies at ESMO Asia 2024
At the conference, AstraZeneca and Daiichi Sankyo will present their case for Dato-DXd in NSCLC, while BioNTech and Merus will reveal promising mid-stage data for their respective cancer candidates.
December 2, 2024
·
4 min read
·
Tristan Manalac
Breast cancer
AstraZeneca, Daiichi Sankyo Push Enhertu to Frontline Breast Cancer With Phase III Data
Analysts at Leerink Partners said in a Monday note that DESTINY-Breast09’s findings “could support an approval” for Enhertu in first-line HER2+ metastatic breast cancer.
April 22, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Wayfinder Biosciences and Daiichi Sankyo collaborate to develop novel RNA-targeting therapies for neurodegenerative disease
April 15, 2025
·
2 min read
Antibody-drug conjugate (ADC)
AstraZeneca and Daiichi Sankyo’s Enhertu Enhances Stomach Cancer Case With Phase III Win
The partners are pushing to expand Enhertu’s list of indications beyond its standing uses in breast, lung and gastric cancers.
March 4, 2025
·
2 min read
·
Tristan Manalac
Policy
Arbitration Dispute Between Daiichi Sankyo and Seagen Ends
A dispute between Daiichi Sankyo Co., Ltd. (TSE: 4568) and Seagen Inc. is now concluded and Seagen has paid Daiichi Sankyo approximately U.S. $47 million in connection with attorneys’ fees and costs plus interest awarded by the arbitrator of the party’s dispute.
June 28, 2024
·
1 min read
Breast cancer
AstraZeneca, Daiichi Sankyo’s ADC Wins First Approval Despite Mixed Data
Datroway, formerly known as Dato-DXd, significantly improved median progression-free survival in a Phase III study but failed to do so for overall survival.
January 21, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Daiichi Sankyo Appoints Hiroyuki Okuzawa as Chief Executive Officer
January 31, 2025
·
3 min read
Approvals
AstraZeneca, Daiichi Sankyo Continue ADC Rally With Enhertu Expansion
Enhertu’s label expansion comes on the heels of the FDA’s approval of the partners’ Datroway for a related type of breast cancer.
January 28, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Nosis Biosciences Announces Research Collaboration and Option Agreement with Daiichi Sankyo to Develop Cell-Targeted RNA Medicines
March 11, 2025
·
2 min read
Cancer
Ono’s FDA Rare Cancer Approval Sets Up Face Off With Daiichi Sankyo
Ono picked up Romvimza—previously known by its active ingredient vimseltinib—from its $2.4 billion acquisition of Deciphera Pharmaceuticals in April 2024.
February 17, 2025
·
2 min read
·
Tristan Manalac
1 of 287
Next
